Osteocalcin ELISA Kit

Produktnummer ABIN456053

Produktdetails Osteocalcin ELISA Kit

Target: Osteocalcin (BGLAP)

Reaktivität: Maus

Nachweismethode: Colorimetric

Methodentyp: Sandwich ELISA

Detektionsbereich: 15.6-1000 pg/mL

Untere Nachweisgrenze: 15.6 pg/mL

Applikation: ELISA

Verwendungszweck: This immunoassay kit allows for the in vitro quantitative determination of mouse Osteocalcin/Bone gla protein, OT/BG concentrations in serum, plasma and other biological fluids.

Proben: Plasma, Serum

Analytische Methode: Quantitative

Spezifität: This assay recognizes recombinant and natural mouse OT.

Kreuzreaktivität (Details): No significant cross-reactivity or interference was observed.

Sensitivität: < 3.9 pg/mL
The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest detectable concentration that could be differentiated from zero.

Produktmerkmale: Mus musculus,Mouse,Osteocalcin,Bone Gla protein,BGP,Gamma-carboxyglutamic acid-containing protein,Bglap

Anwendungsinformationen

Probenmenge: 100 μL

Plattentyp: Pre-coated

Protokoll: The microtiter plate provided in this kit has been pre-coated with an antibody specific to OT. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated polyclonal antibody preparation specific for OT. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then a TMB substrate solution is added to each well. Only those wells that contain OT, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm 2 2 nm. The concentration of OT in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: The Standard, Detection Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20 °C upon being received. The other reagents can be stored at 4 °C.

Details zu Osteocalcin

Target: Osteocalcin (BGLAP)

Andere Bezeichnung: Bglap (BGLAP Produkte)

Synonyme: BGP ELISA Kit, OC ELISA Kit, OCN ELISA Kit, Bglap1 ELISA Kit, Bglap2 ELISA Kit, OG1 ELISA Kit, mOC-A ELISA Kit, Bgp ELISA Kit, Bgpr ELISA Kit, Bgpra ELISA Kit, bgp ELISA Kit, LOC792433 ELISA Kit, ocn ELISA Kit, GLA ELISA Kit, BGLAP ELISA Kit, PMF1 ELISA Kit, bone gamma-carboxyglutamate protein ELISA Kit, bone gamma carboxyglutamate protein ELISA Kit, bone gamma-carboxyglutamate protein S homeolog ELISA Kit, bone gamma-carboxyglutamate (gla) protein ELISA Kit, osteocalcin ELISA Kit, polyamine-modulated factor 1 ELISA Kit, BGLAP ELISA Kit, Bglap ELISA Kit, bglap.S ELISA Kit, bglap ELISA Kit, ocn ELISA Kit, LOC100529177 ELISA Kit, LOC100146589 ELISA Kit

Hintergrund: Osteocalcin (OT) is the most abundant noncollagenous protein in mature bone where it constitutes 1% to 2% of the total protein. Synthesized by osteoblasts, it is incorporated into the bone matrix. Osteocalcin is a 49-residue protein with three gamma-carboxyglutamic acid residues, at positions 17, 21 and 24. These three residues confer on it a very strong ability to bind to hydroxyapatite. Osteocalcin is a noncollagenous protein found in bone and dentin. It is secreted by osteoblasts and thought to play a role in mineralization and calcium ion homeostasis. It has been stipulated that osteocalcin may also function as a negative regulator of bone formation, although its exact role is unknown. It was reported that osteocalcin acts as a hormone in the body, causing beta cells in the pancreas to release more insulin, and at the same time directing fat cells to release the hormone adiponectin, which increases sensitivity to insulin. As osteocalcin is manufactured by osteoblasts, it is often used as a biochemical marker, or biomarker, for the bone formation process. It has been routinely observed that higher serum-osteocalcin levels are relatively well correlated with increases in bone mineral density (BMD) during treatment with anabolic bone formation drugs for osteoporosis, such as Forteo. In many studies, Osteocalcin is used as a preliminary biomarker on the effectiveness of a given drug on bone formation.